Medication non-adherence costs are estimated to be over $100 billion a year in the U.S. Low medication adherence greatly lowers efficacy and also leads to preventable prolongation of illnesses, re-hospitalizations and sometimes death. It would be useful to develop a personalized, affordable solution that significantly enhances the efficacy of medication adherence and intervention, and includes everyone - the patient, provider, pharmacy & caregiver. To address this, IAI and its collaborator, Duke University, have been awarded a new contract entitled, “mSMART: Mobile App based Personalized Solutions and Tools for Medication Adherence of Rx Pills.” IAI's mSMART solution is a mobile app based personalized solution and tool for medication adherence. It consists of an mSMART clinical tool for healthcare or clinical trial professionals, an mSMART app for patients and an mSMART pharmacy tool for pharmacists. The mSMART clinical tool creates a baseline patient adherence behavior profile including baseline EMA status, and provides access to the patient's app to upload profile and medication regimen. The mSMART app interacts with the patient in assessing the patient's adherence behavior and psychiatric or relapse conditions, and offers adherence control actions designed to improve medication behavior. These control actions include providing information to overcome adherence barriers, providing assistance in identifying medication and understanding the regimen, with or without use of a pill dispenser, and generating alerts to providers, family and friends for customized intervention. The key innovative features of mSMART are personalization of the mSMART app using a baseline profile, avatar based interaction sessions with positive reinforcement, an adaptive assessment design, and customized intervention using EMA techniques.